RESUMO
A physio-pathological feature of diabetes mellitus is a significant reduction of ß-pancreatic cells. The growth, differentiation and function maintenance of these cells is directed by transcription factors. Nkx6.1 is a key transcription factor for the differentiation, neogenesis and maintenance of ß-pancreatic cells. We reported that silymarin restores normal morphology and endocrine function of damaged pancreatic tissue after alloxan-induced diabetes mellitus in rats. The aim of this study was to analyze the effect of silymarin on Nkx6.1 transcription factor expression and its consequence in ß cells neogenesis. Sixty male Wistar rats were partially pancreatectomized and divided into twelve groups. Six groups were treated with silymarin (200 mg/Kg p.o) for periods of 3, 7, 14, 21, 42 and 63 days. Additionally, an unpancreatectomized control group was used. Nkx6.1 and insulin gene expression were assessed by RT-PCR assay in total pancreatic RNA. ß-Cell neogenesis was determined by immunoperoxidase assay. Silymarin treated group showed an increase of Nkx6.1 and insulin genic expression. In this group, there was an increment of ß-cell neogenesis in comparison to pancreatectomized untreated group. Silymarin treatment produced a rise in serum insulin and serum glucose normalization. These results suggest that silymarin may improve the reduction of ß pancreatic cells observed in diabetes mellitus.
Assuntos
Proteínas de Homeodomínio/agonistas , Células Secretoras de Insulina/efeitos dos fármacos , Insulina/agonistas , Pancreatectomia , Substâncias Protetoras/farmacologia , Silimarina/farmacologia , Animais , Glicemia/metabolismo , Contagem de Células , Proliferação de Células , Diabetes Mellitus , Modelos Animais de Doenças , Expressão Gênica , Proteínas de Homeodomínio/genética , Proteínas de Homeodomínio/metabolismo , Técnicas Imunoenzimáticas , Insulina/genética , Insulina/metabolismo , Células Secretoras de Insulina/citologia , Células Secretoras de Insulina/metabolismo , Masculino , Ratos , Ratos WistarRESUMO
El Sarcoma de Ewing es el segundo tumor maligno óseo en frecuencia en el niño y en el adulto joven. Tiene su mayor incidencia entre los 10 y los 15 años. Pocos casos están descritos por debajo de los 5 años y por encima de los 30. Presentamos dos casos de Sarcoma de Ewing de la pared torácica. Se describen las características clínicas, radiológicas, anatomopatológicas y sus posibilidades terapéuticas (AU)